Agoracom Blog Home

Archive for the ‘Medical Marijuana Stocks’ Category

« Older Entries
Newer Entries »

Namaste $N.ca Enters Into $30 Million Bought Deal Equity Financing $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:39 AM on Thursday, February 1st, 2018

Nlogo

  • Entered into a letter of engagement with Eight Capital,  along with a syndicate of underwriters
  • 11,765,000 units of the Company , on a “bought deal” basis pursuant to a filing of a short form prospectus, at a price per Unit of $2.55 for gross proceeds of $30,000,750

VANCOUVER, BRITISH COLUMBIA–(Feb. 1, 2018) – Namaste Technologies Inc. (CSE:N)(CSE:N.CN)(CNSX:N)(FRANKFURT:M5BQ)(OTCQB:NXTTF) (“Namaste” or the “Company“), is pleased to announce that it has entered into a letter of engagement with Eight Capital, under which Eight Capital has agreed to purchase, as sole bookrunner and lead underwriter, along with a syndicate of underwriters (the “Underwriters“), 11,765,000 units of the Company (the “Units“), on a “bought deal” basis pursuant to a filing of a short form prospectus, subject to all required regulatory approvals, at a price per Unit of $2.55 (the “Issue Price“) for gross proceeds of $30,000,750 (the “Offering“).

The Company has agreed to grant the Underwriters an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering. If this option is exercised in full, an additional approximately $4,500,000 will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be approximately $34,500,750.

Each Unit will be comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant (a “Warrant“). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of $3.15, for a period of 24 months following the closing of the Offering. If, following the closing of the Offering, the volume weighted average price of the Common Shares on the Canadian Securities Exchange is equal to or greater than $6.00 for any 10 consecutive trading days, the Company may, upon providing written notice to the holders of Warrants, accelerate the expiry date of the Warrants to the date that is 30 days following the date of such written notice.

The Company intends to use the net proceeds of the Offering to fund inventory and for working capital and general corporate purposes.

The closing date of the Offering is scheduled to be on or about February 27, 2018 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the Canadian Securities Exchange and the applicable securities regulatory authorities.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

Sean Dollinger, Chief Executive Officer

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.co.uk

www.everyonedoesit.co.uk

Forward-Looking Information

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
+1 (786) 389 9771
[email protected]

Tags: , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca Enters Into $30 Million Bought Deal Equity Financing $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Tetra Bio-Pharma $TBP.ca Receives Health Canada Approval for Phase 2 #Cannabis Oil Trial in Partnership with Sante Cannabis $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:15 AM on Monday, January 29th, 2018

Logo tetrabiopharma rgb web

  • Announced the approval by Health Canada of a Phase 2 clinical trial
  • Designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil (THC & CBD) to improve uncontrolled chronic pain in cancer and non-cancer patients

OTTAWA, ONTARIO–(Jan. 29, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce the approval by Health Canada of a Phase 2 clinical trial designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil (THC & CBD) to improve uncontrolled chronic pain in cancer and non-cancer patients.

“To our knowledge, this is the first Health Canada-approved phase 2, randomized, double-blind, placebo-controlled clinical trial using encapsulated medical cannabis oil in Canada,” said Bernard Fortier, Tetra Bio-Pharma’s CEO. According to an Eight Capital analysis1, the cannabis oil market is expected to reach 1.5B$ in 2024.

“This is a significant milestone in our mission to become a global bio-pharmaceutical leader in cannabinoids-based drug development. We currently have a strong pipeline of five cannabinoid-based products, all launched last year and using different delivery systems, in various stages towards Health Canada and FDA approval.”

The Phase 2 trial will be conducted with Montreal-based Santé Cannabis, Quebec’s first medical clinic and resource centre specializing in cannabis and cannabinoids for medical purposes.

According to Health Canada data2, the annual Canadian cannabis oil production for medical purposes was 22,766 kg between October 1st 2016 and September 30th 2017, and is growing continuously. In the third quarter of 2017, it grew 24% from Q2 (Apr-Jun) to Q3 (Jul-Sep)1.

Dr. Guy Chamberland, Tetra’s Chief Scientific Officer (CSO), also commented that “there is limited scientific and clinical information on the different doses and ratios of medical cannabis oil in the management of pain. This type of clinical trial is required to generate the urgently needed safety and efficacy data required by physicians and pharmacists for the adequate care of patients”.

“We are excited to launch this trial to build the evidence base for medical cannabis in chronic pain, and to demonstrate the leadership of Santé Cannabis on the world stage” said Dr. Antonio Vigano, Research Director of Santé Cannabis and McGill University Associate Professor of Oncology. “At Santé Cannabis, our team observes the impact that cannabis oil has for our patients. For many, medical cannabis can reduce or even eliminate the need for other pharmacological medications. As clinicians and researchers, we must pursue these critical steps to quantify its benefits and to investigate potential risks.”

These studies are part of the Company’s sales and marketing strategy required to effectively penetrate a physician-pharmacist market. The outcome of these studies will also support Tetra’s overall drug development strategy and it is expected that this will allow Tetra to reduce the overall time-to-market for a number of its cannabinoids-based prescription drugs. The company will also use this data to create novel new products that will allow Tetra to further increase its share in the cannabis oil market.

Last year, Tetra launched a number of drug development programs that are expected to lead to the commercialization of cannabinoid-based prescription drugs, making it one of the world leaders in cannabinoid pharmaceuticals. Tetra’s vision is to develop an evidence-based approach similar to that of any other prescription drug, thereby allowing physicians to prescribe, and pharmacists to dispense, these medicines to patients in need.

After receiving approval of a phase 1 clinical trial for its PPP005 cannabis oil program in mid-January of this year, Tetra is now launching a phase 2 trial to assess if cannabis oil treatment will reduce the amount of concurrent pain medications and the need for rescue medications to control chronic cancer and non-cancer pain. This phase 2 clinical trial is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil. In addition, the study will evaluate the effects on improving symptom burden and on cognition and mood in those chronic pain patients.

Tetra and Santé Cannabis have been preparing for several months to initiate this clinical program. The team at Santé Cannabis has grown to include qualified and experienced personnel in the conduct of clinical trials in compliance with Good Clinical Practices. This trial is driven by the medical experts of Santé Cannabis and will provide much needed safety and efficacy data in this patient population, as well as provide Tetra with critical knowledge of the benefits of different ratios of THC and CBD in pain management.

1: Cannabis Sector, Eight Capital Estimates, July 2017

2: Health Canada Market Data, [https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-use-marijuana/licensed-producers/market-data.html]

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
[email protected]

Tags: , , , ,
Posted in Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Receives Health Canada Approval for Phase 2 #Cannabis Oil Trial in Partnership with Sante Cannabis $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Namaste $N.ca $NXTTF Announces Supply Agreement With Supreme $FIRE.ca to Purchase 1000 kg of Premium Medical Cannabis $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:15 AM on Thursday, January 25th, 2018

Nlogo

  • Announced that its wholly-owned subsidiary, Cannmart, has committed to purchase 1000 kilograms of premium quality medial cannabis from 7ACRES in 2018
  • Agreement represents a significant milestone for Namaste, as its first commitment to a volume purchase of medical cannabis

VANCOUVER, British Columbia, Jan. 25, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(FRA:M5BQ)(OTCMKTS:NXTTF) is pleased to announce that its wholly-owned subsidiary, Cannmart, Inc. (“Cannmart”) and 8528934 Canada Ltd. (“7ACRES”), a wholly-owned subsidiary of The Supreme Cannabis Company, Inc. (“Supreme”) (TSXV:FIRE), have signed a Definitive Supply Agreement (the “Agreement”) whereby Namaste, through its wholly-owned subsidiary, Cannmart, has committed to purchase 1000 kilograms of premium quality medial cannabis from 7ACRES in 2018, commencing on the date that Cannmart becomes a “Licensed Producer” under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”). This Agreement represents a significant milestone for Namaste, as its first commitment to a volume purchase of medical cannabis. Namaste believes that Supreme’s business plan of scaled production of branded, premium cannabis flower aligns itself well with Namaste’s goal of positioning Cannmart as Canada’s largest online retail e-commerce platform for medical cannabis.

Select Terms of the AGREEMENT

Cannmart has agreed to purchase a minimum of 1000 kilograms of medical cannabis in the 2018 calendar year, starting from the date whereby Cannmart becomes a “Licensed Producer” as defined in the ACMPR.
7ACRES has agreed to supply Cannmart with premium medical cannabis at a price of $6,000 per kilogram.
Should Cannmart fail to purchase a minimum of 1000 kilograms of medical cannabis within the 2018 calendar year, Cannmart will be deemed to have purchased, and will pay for, the full 1000 kilograms at the price of $6,000 per kilogram; provided that if 7ACRES cannot supply to Cannmart the amount requested in any given month, then the amount owing shall be reduced by the amount they failed to supply in such month.
Cannmart has agreed to display 7ACRES’ trade-mark on all packaging of the 7ACRES product.

Supreme is focused on producing high quality cannabis through a commitment to carefully curated genetics, quality focused cultivation practices and a post-harvest process that includes a 14-day whole plant drying process and hand finishing of each flower. Namaste anticipates Supreme becoming a key partner in ensuring a strong supply chain for premium medical cannabis flower and looks forward to a long-term, mutually beneficial relationship. Namaste believes this Agreement significantly strengthens its position, and further validates the role the Cannmart facility will soon play in the Canadian cannabis market once the “sales-only” license is received.

Management Commentary
John Fowler, CEO of Supreme comments: “As a cultivation focused Licensed Producer we rely on strong retail partners to provide us access to consumers and favourable brand positioning. We are impressed by the platform being built by Namaste to date, and their innovative strategy to position Cannmart as a “sales-only” entity is a natural fit with our 7ACRES business model. The team at Namaste and Cannmart understand the value of premium cannabis flower and we look forward to taking part in the launch of Cannmart as one of Canada’s first “sales only” Licensed Producers.”

Sean Dollinger, President and CEO of Namaste comments: “We are very pleased to announce this Agreement with Supreme and to make a purchase commitment, which we feel brings significant value in securing supply for premium quality medical cannabis for Cannmart. Namaste feels confident that Supreme’s business strategy as a wholesale producer will lend itself well as Namaste focuses its efforts on the retail component in the medical cannabis industry. We look forward to working with Supreme and their management team and anticipate a long-term relationship that will be beneficial for both companies over the next several years.”

About Supreme
Supreme is a Canadian publicly traded company committed to becoming a leading cultivator and distributor of sun grown cannabis through its wholly-owned subsidiary 7ACRES. 7ACRES is a federally licensed producer of medical cannabis pursuant to the ACMPR operating inside a 342,000 sq. ft. Hybrid Greenhouse facility. The Hybrid Greenhouse combines the best technology of indoor production with the efficiencies and sustainability of a greenhouse, in a single large-format production footprint. Please visit www.supreme.ca and www.7acres.com for more information.

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Forward Looking Information
Certain statements made in this press release may constitute forward-looking information under applicable securities laws. These statements are based on Namaste’s current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although Namaste believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because no assurance can be given that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in Namaste’s disclosure documents which can be found under Namaste’s profile on sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

Agreement.namastetechnologies.com
Agreement.namastevaporizers.co.uk
Agreement.everyonedoesit.co.uk
Agreement.australianvaporizers.com.au

Tags: , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Announces Supply Agreement With Supreme $FIRE.ca to Purchase 1000 kg of Premium Medical Cannabis $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Aurora $ACB.ca finally wins CanniMed $CMED.ca in Canada’s biggest marijuana deal yet $TBP.ca $N.ca $MCOA

Posted by AGORACOM-JC at 12:10 PM on Wednesday, January 24th, 2018

  • Aurora Cannabis Inc. has struck a friendly deal valued at $1.1 billion to buy rival licensed producer CanniMed Therapeutics Inc
  • The deal, which will be Canada’s largest in the marijuana sector, also means CanniMed will abandon its plans to acquire Newstrike Resources Ltd., whose shareholders had already voted in favour of a takeover by CanniMed

EDMONTON — Aurora Cannabis Inc. has struck a friendly deal valued at $1.1 billion to buy rival licensed producer CanniMed Therapeutics Inc., bringing an end to a lengthy hostile takeover battle between the marijuana companies.

The deal, which will be Canada’s largest in the marijuana sector, also means CanniMed will abandon its plans to acquire Newstrike Resources Ltd., whose shareholders had already voted in favour of a takeover by CanniMed.

CanniMed will pay a $9.5-million break fee to Newstrike as a result of its decision.

Shares in CanniMed were up 16 per cent by midmorning after shooting up 22 per cent directly after the news. Aurora was up half a per cent. Newstrike trading was halted but the stock fell 20 per cent when trading resumed.

“We are very pleased to have come to terms with CanniMed on this powerful strategic combination that will establish a best-in-class cannabis company with operations across Canada and around the world,” Aurora chief executive Terry Booth said.

“Market recognition of Aurora’s continued performance and strategy execution since we first announced our intention to acquire CanniMed allows us to share that benefit directly with CanniMed shareholders by increasing the offer price, as well as by offering a cash component.”

CanniMed had argued that Aurora’s earlier all-stock offer valued at up to $24 per share for the company was too low, given the wild swings in marijuana stocks.

The two appeared to have reached a truce last week, agreeing to talks after a very public and litigious war of words.

Aurora’s new offer includes a cash component. Under the agreement announced Wednesday, CanniMed shareholders will receive 3.4 Aurora shares or a combination of cash and shares for each CanniMed share they hold.

Based on an implied Aurora share price of $12.65 and the 3.40 exchange ratio, the companies said the new offer would equate to $43 per share.

However, Aurora shares closed at $14.79 on the Toronto Stock Exchange on Tuesday making the offer worth about $50.29. CanniMed shares closed at $37.51.

The total amount of cash available under the deal is capped at $140 million. Assuming maximum cash elections, each CanniMed shareholder would receive $5.70 in cash and 2.9493 Aurora shares.

CanniMed chief executive Brent Zettl said the deal was a testament to the team at CanniMed.

“This transaction clearly confirms that the company has been highly successful in becoming a preeminent global leader in the medical cannabis industry,” Zettl said.

The new offer and the transaction are subject to customary closing conditions, including Competition Act approval.

Source: http://business.financialpost.com/commodities/agriculture/newsalert-aurora-cannabis-to-buy-cannimed-therapeutics-in-deal-valued-at-1-1b

Tags: , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc., Tetra Bio-Pharma Inc. | Comments Off on Aurora $ACB.ca finally wins CanniMed $CMED.ca in Canada’s biggest marijuana deal yet $TBP.ca $N.ca $MCOA

BMO $BMO.ca marks first foray by a major Canadian bank in #marijuana sector with $175M deal $TBP.ca $N.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 2:42 PM on Thursday, January 18th, 2018

  • Bank of Montreal broke new ground Wednesday for the “Big Five” Canadian lenders with its participation in a major marijuana deal
  • Canopy Growth Corp., Canada’s largest licensed producer of medical cannabis, announced an approximately $175-million bought-deal offering Wednesday

Smiths Falls, Ont.-based Canopy Growth Corp., Canada’s largest licensed producer of medical cannabis, announced an approximately $175-million bought-deal offering Wednesday of a little more than five million shares of the company.

Canopy noted in a release that GMP Securities LP and Bank of Montreal-owned BMO Capital Markets were leading the transaction for the company as joint bookrunners, marking the first time a major Canadian bank has helped head an equity financing for a publicly traded company in the medical marijuana industry.

“This is the first time a major Canadian bank-owned brokerage has participated in a cannabis securities issue,” wrote Chris Damas, editor of the BCMI Cannabis Report.

A spokesperson for Canopy confirmed that the transaction marked the first such foray by a Big Five Canadian bank.

“Although this does not guarantee participation in the cannabis sector by all six of the largest Canadian Schedule 1 banks (BMO had already been a banker for cannabis companies), it is very positive for the sector, all things being equal,” Damas added.

Other major Canadian banks have yet to dive into the country’s growing cannabis sector in the same way BMO has, and are likely hesitant to do so given their significant business in the United States, where marijuana is still illegal under federal law. But some banks, including BMO, have provided business accounts for cannabis companies, according to Bloomberg.

That stance may now be starting to soften amid a fundraising spree in the Canadian marijuana industry, which had been taking place without the country’s biggest banks. Companies involved in the already legal medical pot business have been seeking funding to serve the coming recreational market set to be legalized by the federal government this summer.

Royal Bank of Canada told the Financial Post in a statement last week that it “currently does not provide banking services to companies engaged in the production and distribution of marijuana.”

“We recognize that the legislative landscape is evolving and we are undergoing a review of our policies,” added the lender.

A spokesperson for Bank of Nova Scotia told the Post on Friday that “we must balance that with our commitment to effectively manage all business risks.”

“While we understand there is a robust debate in Canada and abroad, our priority is to manage risk for our customers and stakeholders to ensure they are protected,” said Scotiabank’s Rick Roth in an email. “Should there be significant change to industry legislation or regulation, we will revisit our risk assessment and make risk policy adjustments if warranted.”

Toronto-Dominion Bank and the Canadian Imperial Bank of Commerce either declined to comment or had yet to respond as of Thursday morning.

Canopy said its agreement with the underwriters includes an over-allotment option for them, allowing for the purchase of up to 759,000 additional shares at the offering price of $34.60 per share, worth nearly $26.3 million. The company said that the deal is expected to close on Feb. 7, subject to some conditions, and that the net proceeds will be used “for capital expenditures for capacity expansion, working capital, and general corporate requirements.”

Source: http://business.financialpost.com/investing/bank-of-montreal-marks-first-for-major-canadian-lenders-with-175m-marijuana-deal

Tags: , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks, Namaste Technologies Inc., Tetra Bio-Pharma Inc. | Comments Off on BMO $BMO.ca marks first foray by a major Canadian bank in #marijuana sector with $175M deal $TBP.ca $N.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX

Namaste $N.ca Announces 5% Equity Purchase LOI with Cannbit Ltd. $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:09 AM on Thursday, January 18th, 2018

Nlogo

  • Company has signed a non-binding Letter of Intent with Israeli medical cannabis producer, Cannbit Ltd
  • Namaste would acquire an equity position of 5% in Cannbit through an investment to be made in a proportion to be determined and agreed by both parties

VANCOUVER, British Columbia, Jan. 18, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (FRANKFURT:M5BQ), (OTCMKTS:NXTTF) is pleased to announce that the Company has signed a non-binding Letter of Intent (“LOI”) with Israeli medical cannabis producer, Cannbit Ltd (“Cannbit)” whereby the companies propose to enter into a share purchase agreement and/or a subscription agreement (the “Agreement”) whereby Namaste would acquire an equity position of 5% in Cannbit through an investment to be made in a proportion to be determined and agreed by both parties. Cannbit will also offer Namaste a first right of refusal to purchase an additional 5% equity in shares at the same valuation.

Further to the Company’s September 15th, 2017 announcement of signing a Wholesale Supply Agreement (“Supply Agreement”) with Cannbit, Namaste intends to purchase high-quality medical grade cannabis from Cannbit through the Company’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”). The Company is pleased to have the opportunity to participate in an equity position with Cannbit and in developing a long-term relationship that will be mutually beneficial to both parties. Cannmart is a late stage applicant for an Access to Cannabis for Medical Purposes Regulations (“ACMPR”) medical cannabis “sale-only” license. Through Cannmart, Namaste plans to offer the largest variety of medical cannabis products to its patients through the sourcing of both domestic and internationally imported products. Namaste hopes to leverage its vast expertise with e-commerce, conversion rate optimization and enterprise technology to create Canada’s leading online marketplace for medical cannabis.

Terms of the LOI:

  • Namaste will make an investment in Cannbit in exchange for 5% equity, whereby the amount will be determined by a valuation agreed to by both parties.
  • Namaste will have a first right of refusal to purchase an additional 5% equity position in Cannbit, at the same valuation as originally agreed upon, for a period of one year from the date of execution of the proposed agreement.
  • Closing of the proposed agreement will be contingent upon negotiating and execution of definitive documentation and approval of the terms of the agreement by each party’s respective board of directors and shareholders, if applicable, and by the Canadian Securities Exchange, if applicable.

Namaste’s strategic investment in Cannbit, as well as other domestic and international licensed producers of medical cannabis, will bring value to the company in securing strong partnerships with leading cannabis cultivators to ensure ample supply of the largest variety of high-quality medical cannabis in the Canadian market. Namaste plans to seek additional opportunities by implementing Cannmart’s business model in other regions where the Company maintains significant market share.

Sean Dollinger, President and CEO of Namaste comments: “We’re very much looking forward to working with Cannbit and their team to import exceptionally high-quality medical cannabis into the Canadian market. Namaste expects to see strong value in this investment, as well as through the supply arrangement with Cannbit. We will continue to seek relationships with leading cultivators domestically and abroad. We are highly focused on creating a superior user experience and better availability of products for our patients, and believe this transaction will help us achieve that goal. Thank you to Cannbit’s management team for working hard to secure this LOI and Supply Agreement. We look forward to many years of business together and are excited at the opportunity to give Canadians access to the Israeli cannabis market.”

Yaron Razon, President and CEO of Cannbit Comments “We are very excited to have this partnership and strategic cooperation with Namaste. We believe Namaste is well-positioned with an impressive global marketing and distribution platform and led by a brilliant management team. Together with Namaste, Cannbit will reach many patients across the world with premium medical grade cannabis to help treat their health conditions. We anticipate exploring new opportunities with Namaste and are looking forward to working together soon.”

About Cannbit Ltd.

Cannbit is focused on growing high-quality medical-grade cannabis with advanced technology and agriculture platform while utilizing the best human resources to produce the highest level of quality available that will effectively treat a wide range of illnesses. The Israeli government is expected to approve the export of medical cannabis and Cannbit intends to become Israel’s leading exporter for medical cannabis to legal jurisdictions around the globe. Cannbit’s facility is 4,000 square meters with an additional 10,000 square meters available for expansion and is located in Neot Hakikar, an area well known in the Israeli agricultural community with clear advantages in the cold seasons. Our cultivation is carried out in a sophisticated greenhouse that provides ideal conditions for a variety of cannabis strains. Cannbit’s management is comprised of a group of industry professionals in relevant disciplines.

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk
www.australianvaporizers.com.au

Tags: , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca Announces 5% Equity Purchase LOI with Cannbit Ltd. $AERO $CBDS $CGRW $APH.ca $GBLX

Namaste $N.ca $NXTTF Reaffirms Position on No US Exposure and Provides Corporate Response to Recision of Cole Memo and CSA Statement $ATT.ca $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:36 AM on Wednesday, January 17th, 2018

Nlogo

  • Reaffirms its commitment to operations exclusively within medical or recreational cannabis legal jurisdictions
  • Company would like to express very clearly that it does not hold any US assets nor does it intend on participating in any US operations or investments

VANCOUVER, British Columbia, Jan. 17, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (FRANKFURT:M5BQ), (OTCMKTS:NXTTF) would like to reaffirm its commitment to operations exclusively within medical or recreational cannabis legal jurisdictions. Further to the Company’s Nov 28, 2017 press release, and in lieu of the recent rescission of the Cole Memorandum by US Attorney General Jeff Sessions, Namaste’s position on staying out of the US cannabis market remains firm. The Company would like to express very clearly that it does not hold any US assets nor does it intend on participating in any US operations or investments. Namaste is highly focused on the expansion of its Canadian operations through the launch of its online medical cannabis marketplace. Management will have no involvement in operations or investments in any illegal jurisdictions which present any risk to the Company and/or its shareholders.

On January 12, 2018, the Canadian Securities Administrators (“CSA”) issued a statement following the rescission, whereby the CSA gave notice that it would re-examine its disclosure-based policy in relation to Canadian cannabis companies with any US operations or investments. Namaste believes that the CSA’s statement is in-line with the Company’s position and short-term outlook on the cannabis market in the United States.

Namaste will continue to focus on expansion of its international operations in progressive, legal markets by leveraging its technology and existing databases of cannabis consumers in countries around the world. Namaste, through its wholly owned subsidiary, Cannmart Inc. (“Cannmart”) is developing an online marketplace for medical cannabis that will offer patients the largest variety of product sourced from domestic and international producers. The launch of Cannmart is significant to Namaste, as the Company intends to follow the same strategy in other legal markets where it has established a strong presence.

Management Commentary
Sean Dollinger, President and CEO of Namaste comments: “We’re very pleased to have divested our US assets and operations. Namaste will continue focusing its efforts on progressive, legal markets like Canada and emerging legal cannabis markets like Australia and will remain uninvolved with any US cannabis operations until there are major changes to US federal laws.”

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk
www.australianvaporizers.com.au

Tags: , , , , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Reaffirms Position on No US Exposure and Provides Corporate Response to Recision of Cole Memo and CSA Statement $ATT.ca $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Namaste $N.ca $NXTTF Announces Participation as Lead Order in Atlas Growers Private Placement and Secures 20% of Net Production $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:17 AM on Tuesday, January 16th, 2018

Nlogo

  • Participating as a lead order in a private placement offering by Atlas Growers Ltd.
  • In consideration of the investment, Atlas and Namaste’s wholly owned subsidiary, Cannmart Inc. have entered in to a Supply Agreement
  • Atlas agreed to guarantee supply to Cannmart by offering first right of refusal for a minimum of 20% of the net production of medical cannabis through Atlas

VANCOUVER, British Columbia, Jan. 16, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (FRANKFURT:M5BQ), (OTCMKTS:NXTTF) is pleased to announce that the Company is participating as a lead order in a private placement offering (“Private Placement”) by Atlas Growers Ltd. (“Atlas”), which is a late-stage applicant for an Access to Cannabis for Medical Purposes (“ACMPR”) cultivation and sales license. In consideration of the investment, Atlas and Namaste’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”) have entered in to a Supply Agreement (the “Supply Agreement”) whereby Atlas agrees to guarantee supply to Cannmart by offering first right of refusal for a minimum of 20% of the net production of medical cannabis through Atlas.

The Company’s participation in the Private Placement and subsequent Supply Agreement offer significant value to Namaste shareholders not only as an investment, but also in securing a reliable supply of high quality medical cannabis. The Company believes Atlas’ strong management team and business plan provide a strategic partnership opportunity with Atlas to ensure a guaranteed cannabis supply to Namaste, while at the same time broadening Atlas’ exposure to the market via Cannmart’s online retail channels. Namaste has completed the Subscription Agreement under the terms of the Private Placement, for C $200,000 in exchange for 200,000 Class B Common shares of Atlas stock at a price of C $1.00 per common share. The Supply Agreement will allow Cannmart to purchase bulk quantities of medical cannabis from Atlas based on the terms below.

Supply Agreement Terms

  • Atlas commits to Cannmart a first right of refusal to purchase up to 20% of Atlas’ production
  • The term of the Supply Agreement is 24 months
  • Purchase orders are to be submitted at least 14 days in advance of requested delivery date
  • Payment terms are 30 days from delivery of a purchase order
  • Cannmart will be responsible for delivery charges
  • The Supply Agreement is subject to both companies receiving their ACMPR licenses.

Namaste will continue to explore additional opportunities for investments in domestic and international medical cannabis producers as it sees great value in securing equity and building a strong and reliable supply chain for Cannmart’s patients. Namaste plans to leverage its vast e-commerce expertise and technology, along with its existing consumer databases and site traffic, to create the largest online marketplace for medical cannabis in Canada. This strategic investment in Atlas clearly defines the Company’s strategy in developing strong supply relationships to achieve its goals. The Canadian market offers some unique opportunities as it relates to craft and/or boutique producers, and Namaste believes this niche will add significant value to its platform.   Canada has a long history of producing some of the highest quality and most sought-after cannabis in the world, and it is Namaste’s intention to ensure all producers have access to its distribution channels. Namaste expects to see a growing demand for the cannabis produced in these markets, much like that seen in the craft beer and wine industry. This partnership demonstrates the Company’s intention to leverage a broad range of supply chains, in an attempt to meet the wants and needs of our patients.

Management Commentary
Sean Dollinger, President and CEO of Namaste comments: “We’re very excited to be participating in this opportunity with Atlas and their team. We believe that Atlas will be an amazing strategic partner for Namaste in its ability to guarantee a reliable supply of cannabis for Cannmart. We are looking forward to working with Atlas to provide value and exposure for their brand. Namaste will continue to seek opportunities for partnerships with large and small ACMPR producers and will also focus on growing our vendor database to include premium craft cannabis brands. The opportunity to participate in this private placement brings value to the company as an investment but also in implementation of our strategy to become the most diversified marketplace for medical cannabis.”

Sheldon Croome, President and CEO of Atlas comments: “Our team is pleased to work with Namaste by providing our array of high quality cannabis products to their customers. In partnering with Namaste, both companies gain a significant strategic advantage as the market moves towards recreational legalization in 2018, and as the medical cannabis market expands. Namaste will be instrumental in bringing Atlas’ products to Eastern Canadian customers with the fastest possible delivery times, which we feel to be of excellent value to the end consumer. We are excited to bring additional value to Namaste and look forward to a strong, long term partnership.”

About Namaste Technologies Inc. 
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk
www.australianvaporizers.com.au

Further information on Atlas can be accessed through the link below:

www.atlasgrowers.com

Tags: , , , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Announces Participation as Lead Order in Atlas Growers Private Placement and Secures 20% of Net Production $AERO $CBDS $CGRW $APH.ca $GBLX

Tetra Bio-Pharma $TBP.ca Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil) $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:13 AM on Tuesday, January 16th, 2018

Logo tetrabiopharma rgb web

  • Received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD),
  • Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005

OTTAWA, ONTARIO–(Jan. 16, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005.

According to Health Canada data1, the annual Canadian cannabis oil production for medical purposes was 22,766 kg between October 1st 2016 and September 30th 2017, and is growing continuously. In the third quarter of 2017, it grew 24% from Q2 (Apr-Jun) to Q3 (Jul-Sep)1. According to an Eight Capital analysis2, the cannabis oil market is expected to reach 1.5B$ in 2024.

The launch of this trial is the first step in Tetra’s plans to commercialize natural health products with its partners. The corporation will develop cannabis-based supplements for commercialization under the Natural Health Product regulations in Canada and in other countries where regulatory authorities have a recognized pathway for approval and commercialization of such products. The trial will eventually include formulations that will be registered as drugs under Health Canada’s TPD regulatory pathway. “Tetra Bio-Pharma Inc. seeks to become an important player in the retail market post legalization and this clinical trial is part of the sales and marketing strategy required to effectively penetrate the lucrative pharmacy and health stores retail markets,” states Bernard Fortier, CEO of Tetra.

Tetra’s vision is to develop an evidence-based approach, thereby allowing pharmacists to dispense these medicines to patients in need. Despite the growing popularity of cannabis oils, physicians and pharmacists across Canada are still hesitant to support the use of these products because of the lack of data supporting its medical use. Dr. Guy Chamberland, Chief Science Officer, commented: “This trial is part of Tetra’s corporate strategy to develop the science required to commercialize safe and efficacious cannabis oil products post-legalization and to create innovative oral drug formulations for the development of medicines in the management of pain, anxiety and the treatment of cancer.”

In that respect, Tetra’s scientific team is supporting the strategy by initiating a phase 1 clinical trial to characterize the safe use of these cannabis oil medicines in humans. Tetra has worked with Altasciences Clinical Research for the preparation of the Clinical Trial Application (CTA) for the conduct of a double-blind phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple daily doses of cannabis (Delta-9-tetrahydrocannabinol/Cannabidiol) oil capsules administered to healthy human volunteers. Health Canada issued a No Objection Letter for the conduct of the phase I clinical trial on January 12nd, 2018. Altasciences Clinical Research will be initiating the clinical trial activities in the coming weeks. The cannabis oil is manufactured by Tetra’s partner, Aphria Inc.

1: Health Canada Market Data, [https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-use-marijuana/licensed-producers/market-data.html] 2: Cannabis Sector, Eight Capital Estimates, July 2017About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
[email protected]

Tags: , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil) $AERO $CBDS $CGRW $APH.ca $GBLX

Marijuana Company of America Launches New CBD Product hempSMART™ Pet Drops $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:37 AM on Thursday, January 11th, 2018

15233 mcoa

  • Release of hempSMART™ Full Spectrum Pet Drops formulated for cats and dogs.
  • Formulated with 250mg of full spectrum non-psychoactive Cannabidiol (CBD) derived from industrial hemp

 

ESCONDIDO, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) — via NetworkWire – MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTC:MCOA), an innovative hemp and cannabis corporation, is pleased to announce the release of hempSMART™ Full Spectrum Pet Drops formulated for cats and dogs.

Each bottle of hempSMART Full Spectrum Pet Drops is formulated with 250mg of full spectrum non-psychoactive Cannabidiol (CBD) derived from industrial hemp. The new specially formulated product contains naturally occurring CBD derived from hemp seed oil, full spectrum hemp extract, fractionated coconut oil, and a rich bacon flavor.

Donald Steinberg, MCOA’s CEO said, “Our new hempSMART product is a natural option for pet owners who care about supporting their animals’ healthy energy levels as well as optimizing their health. Our hempSMART product line will continue to expand to other popular areas of consumer interest to give our affiliates what they need to succeed.”

In reviewing pet supplement trends for 2017, Watson, Inc.’s Mona Hollums observed that natural pet supplement sales nearly doubled between 2008 and 2014. With the increasing focus on pet health, the market for pet supplements is projected to show significant and continuing expansion. Projections show that U.S. retail sales of pet supplements and nutraceuticals treats will grow 3%-5% annually, bringing the market to $1.6 billion. Globally, the pet supplement market is also expected to grow even further. Between 2016-2020, sales are projected to increase over 5% and will continue to yield lucrative investment payouts.

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™â€, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact: 
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , , , , ,
Posted in Featured, Marijuana Company of America, Medical Marijuana Stocks | Comments Off on Marijuana Company of America Launches New CBD Product hempSMART™ Pet Drops $AERO $CBDS $CGRW $APH.ca $GBLX

« Older Entries
Newer Entries »